Screener
Taysha Gene Therapies, Inc. TSHA Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Taysha Gene Therapies, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesAndOtherLiabilities.
The source filing: Taysha Gene Therapies, Inc.’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-344610
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $9,164 | $6,275 |
| Accrued expenses and other current liabilities | 16,811 | 20,277 |
| Total current liabilities | 25,975 | 26,552 |
| Term loan, net | 49,260 | 50,106 |
| Operating lease liability, net of current portion | 6,291 | 18,172 |
| Other non-current liabilities | 1,641 | 1,552 |
Item 1. Financial Statements.
FAQ
- What is Taysha Gene Therapies, Inc.'s accrued expenses?
- Taysha Gene Therapies, Inc. (TSHA) reported accrued expenses of $16.81M in Q2 2026.
- How has Taysha Gene Therapies, Inc.'s accrued expenses changed year-over-year?
- Taysha Gene Therapies, Inc.'s accrued expenses increased by 38.4% year-over-year, from $12.15M to $16.81M.
- What is the long-term trend for Taysha Gene Therapies, Inc.'s accrued expenses?
- Over 5 years (2020 to 2025), Taysha Gene Therapies, Inc.'s accrued expenses has grown at a 31.6% compound annual growth rate (CAGR), from $5.14M to $20.28M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Taysha Gene Therapies, Inc.'s accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude